Roivant Sciences Ltd Ordinary Shares ROIV

Morningstar Rating
$38.66 −0.31 (0.78%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ROIV is trading at a LOCK|LqG?z@ premium.
Price
$38.96
Fair Value
LOCK|.!#<nJq%
Uncertainty
LOCK|T?
1-Star Price
LOCK|.Y&Rj#%
5-Star Price
LOCK|.!gdzZ%
Economic Moat
LOCK|j!
Capital Allocation
—

News

Trading Information

Previous Close Price
$38.96
Day Range
$38.46–39.51
52-Week Range
$19.96–42.50
Bid/Ask
$35.50 / $40.00
Shares Outstanding
724.56M
Market Cap
$28.01B
Volume/Avg
4M / 8M

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
672.24
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
0.71%

Company Profile

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Core
Total Number of Employees
721

Valuation

Metric
ROIV
Price/Earnings (Normalized)
—
Price/Book Value
6.96
Price/Sales
672.24
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
ROIV
Quick Ratio
0.00
Current Ratio
15.56
Interest Coverage
—
Quick Ratio
ROIV

Profitability

Metric
ROIV
Return on Assets (Normalized)
−14.59%
Return on Equity (Normalized)
−17.91%
Return on Invested Capital (Normalized)
−22.77%
Return on Assets
ROIV

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|$#!^F!LOCK|@>lC&$131B
Regeneron Pharmaceuticals Inc
REGN
LOCK|ktWZX>rLOCK|^J?vW$95B
Moderna Inc
MRNA
LOCK|hkqrMd>LOCK|RyQ$79B
argenx SE ADR
ARGX
LOCK|mm!rT#LOCK|>s$59B
BeOne Medicines Ltd ADR
ONC
LOCK|WqYY$NLOCK|d@$45B
Royalty Pharma PLC Class A
RPRX
LOCK|z%!Y%bp%LOCK|z?^t$30B
Incyte Corp
INCY
LOCK|x$>%J%@LOCK|@y$23B
BioNTech SE ADR
BNTX
LOCK|Py^gVbLOCK|Y>$20B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|Ppwm$lLOCK|V@p>N$19B
BridgeBio Pharma Inc
BBIO
LOCK|SPSTCdLOCK|>^$15B

Sponsor Center